1. Home
  2. CIM vs MNKD Comparison

CIM vs MNKD Comparison

Compare CIM & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chimera Investment Corporation

CIM

Chimera Investment Corporation

N/A

Current Price

$8.33

Market Cap

1.0B

Sector

Real Estate

ML Signal

N/A

Logo MannKind Corporation

MNKD

MannKind Corporation

N/A

Current Price

$3.73

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CIM
MNKD
Founded
2007
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.2B
IPO Year
2007
2004

Fundamental Metrics

Financial Performance
Metric
CIM
MNKD
Price
$8.33
$3.73
Analyst Decision
Hold
Strong Buy
Analyst Count
5
9
Target Price
★ $14.17
$8.08
AVG Volume (30 Days)
1.4M
★ 3.3M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 21.33%
N/A
EPS Growth
★ 56.36
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $348,966,000.00
Revenue This Year
N/A
$26.63
Revenue Next Year
N/A
$14.81
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 22.23
52 Week Low
$8.11
$2.23
52 Week High
$14.18
$6.51

Technical Indicators

Market Signals
Indicator
CIM
MNKD
Relative Strength Index (RSI) 33.31 61.07
Support Level $8.11 $3.24
Resistance Level $13.82 $4.28
Average True Range (ATR) 0.25 0.15
MACD 0.10 0.08
Stochastic Oscillator 37.14 95.65

Price Performance

Historical Comparison
CIM
MNKD

About CIM Chimera Investment Corporation

Chimera Investment Corporation is an internally managed REIT whose principal business objective is to provide attractive risk-adjusted returns and distributable income through investment performance linked to mortgage credit fundamentals. Through its mortgage lending, investment management, and advisory services platforms, the Company operates as a fully integrated mortgage business that originates, manages, and invests in a diversified range of mortgage assets. The Company invests, directly or indirectly, generally on a levered basis across a spectrum of mortgage assets, including residential mortgage loans, Non-Agency RMBS, Agency RMBS, Agency CMBS, MSRs, business purpose and investor loans, including RTLs, and other real estate-related assets.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: